The Center for State Control of Medicines, Equipment and Medical Devices (Cecmed) unveiled this Friday the authorization for the emergency use of the monoclonal antibody Itolizumab in the protocol for treatment of critically ill and critically ill patients of COVID-19.
<br />Itolizumab was introduced into the protocol for COVID-19 in April 2020 for the treatment of critically ill and critically ill patients, and the research was later modified and used in moderate patients.
<br />The results with this product are very significant in reducing the mortality data. In severe patients, he said, the recovery rate was higher than 80% and in the case of moderate or cared patients with a high propensity to worsen their clinical condition, more than 95% recovered successfully.
<br />The product, which is a significant contribution to the treatment of sick patients by COVID-19, is not only the result of the CIM but also of several research sites, intensive therapies, and clinicians in 10 hospital institutions, with emphasis on the Manuel hospital. "Piti" Fajardo, from Villa Clara.
<br />These results are not only based on the data obtained from the application in Cuba, but were complemented by a controlled trial carried out by the India Biocon Company, with which the CIM maintained close relationships for more than a decade and has carried out the development of this product together, which made it possible to confirm the data of our country and with its use decreased mortality in that country. The regulatory authority of India has also authorized the use of this monoclonal antibody.
<br />This approval allows us to use it in the Cuban protocol and opens the doors for it to be used in other countries.
<br />
<br />
Comment
Comments
Frequent Questions
How can I access the therapeutic vaccines against lung cancer?
Cuba has 2 therapeutic vaccines for advanced lung cancer:
CIMAvax EGF ® and VAXIRA ® (racotumomab). Both therapeutic vaccines have sanitary registration in the indication of stage III and IV advanced non-small cell lung cancer (NSCLC), after the first line of chemotherapy. The main clinical benefit of these vaccines has been shown to be increased survival and improved quality of life, as well as a broad safety profile.
How to acquire the vaccines?
Foreigners should contact the Cuban Medical Services who will evaluate each case as part of a comprehensive patient care program, with commercial value.
-Cuban Medical Services. Web page:
www.smcsalud.cu.; E-mail: smc@smcsalud.cu
Phone: (537) 209-0977 Fax: (537) 203-1590.
You can also make your request for care expressing the reason for your request, a medical summary and personal data directly to:
International Clinic of the Hermanos Ameijeiras Hospital.
Calle San Lázaro # 701 esq. to Belascoaín, Havana Center, Havana, C.P: 10400, Cuba.
Telephone: (537) 8761029, (537) 8761030, (537) 8761683. Email: turismomedico@hha.sld.cu
International Health Center
La Pradera Calle 15 between 222 A and 234, Siboney neighborhood, Playa Municipality, Havana, Cuba
Telephone: (+537) 273 7467 Ext. 403 (+537) 2737202. Email: comercia@cislapradera.cu